"id","uuid:ID","versionIdentifier","instanceType","rationale"
"StudyVersion_1","f51098a7-520f-48ae-81e8-b6a604a055c8","2","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
